Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Launched by CHU DE QUEBEC-UNIVERSITE LAVAL · Feb 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a special type of therapy called cognitive-behavioral therapy (CBT) designed to help women who carry the BRCA1 or BRCA2 gene mutations and are worried about their cancer coming back. The research aims to see if this therapy can lower their fear of cancer recurrence and improve their overall well-being. Participants will either start the therapy right away or wait a little longer before beginning. They will take part in online group sessions once a week for four weeks and fill out surveys before, right after, and a few months after the therapy to track their progress.

To be eligible for this trial, women must have completed their main cancer treatment at least three months ago but no more than ten years ago, be at least 18 years old, and be able to read and understand French. They should also have a high level of fear about cancer coming back. However, women with certain health issues, like advanced cancer or severe mental disorders, may not qualify. This study is important because it could help many women manage their fears and improve their quality of life after facing cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1) Have completed primary treatment for breast or ovarian cancer (with the exception of adjuvant hormone therapy) for at least 3 months but no more than 10 years.
• • 2) Be known to carry a BRCA1/2 genetic mutation.
• • 3) Have a clinical level of fear of cancer recurrence as defined by a score of 13 or more on the Fear of Cancer Recurrence Inventory severity subscale.
• • 4) Be at least 18 years of age.
• • 5) be able to read, understand and express herself in French.
• Exclusion Criteria:
• • 1) Have distant metastases.
• • 2) Have a known cognitive disorder.
• • 3) Have a known severe psychological disorder (e.g., psychotic disorder, bipolar disorder, substance abuse or dependence disorder).
• • 4) Women taking psychotropic medication are eligible, but only if the dosage has been stable for at least one month.